[A21-63] Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2021
Project no.:
A21-63
Commission:
Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older
Result of dossier assessment:
Added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G19-04 | Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A23-135 | Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |